A recent online article—"A Billion Dollar Market Just Waiting for a New Oral Mucositis Drug”—published by Baystreet.ca favorably mentions Brilacidin-OM as one of five promising drug candidates—the “Top Contenders”—targeting the Oral Mucositis (OM) market.
Innovation Pharmaceuticals has completed its randomized double-blind Phase 2 Trial of Brilacidin-OM (see NCT02324335), with topline results having been released.
Results revealed a clear reduction in the incidence of Severe OM (WHO Grade ≥ 3) in patients treated with Brilacidin-OM as compared to those on placebo. Brilacidin also appeared generally safe and well-tolerated across the full safety population.
The Company is now preparing to move the Brilacidin-OM program forward.